Here's Why TG Therapeutics Jumped 35.5% in December
Shares of TG Therapeutics (NASDAQ: TGTX) gained over 35% last month, according to data provided by S&P Global Market Intelligence. The pharma stock ended the year on a high note thanks to two impressive data presentations at the Annual Meeting of the American Society of Hematology (ASH).
The company is developing two separate triple-combination therapies as treatments for relapsed (meaning a cancer has returned after treatment) or refractory (meaning a cancer was resistant to treatment) non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Both triple combinations achieved very high response rates in small, early-stage studies.
That was enough to propel shares to a 170% gain in 2019.
Source Fool.com
